急性ST段抬高心肌梗死患者溶栓联合氯吡格雷治疗效果观察

目的对急性ST段抬高心肌梗死患者联合运用溶栓+氯吡格雷进行治疗,对其临床治疗效果进行探讨与分析。方法本研究共纳入研究对象84例,均为2007年1月到2014年1月我院收治的急性ST段抬高心肌梗死患者,在患者自愿的基础上依照随机数字表的方式给予其中42例常规溶栓治疗(对照组),另42例给予溶栓+氯吡格雷联合治疗(观察组),观察两组患者心绞痛发作次数以及持续时间,并对比两组再次发生心梗的几率与病死率。结果经相应治疗,在心绞痛发作次数以及持续时间上,观察组要显著低于对照组(P0.05);在再次心梗的发生率以及病死率上,观察组明显比对照组低(P0.05)。在不良反应率上,两组差异不显著不具有统计学意义(P0.05)。结论氯吡格雷联合溶栓在治疗急性ST段抬高心肌梗死症状上能够起到显著的效果,使患者心绞痛的发作次数以及再次发生心梗的几率得到降低,对患者预后质量进行明显改善,有着重要的临床使用价值。

Clinical efficacy of thrombolysis combined with clopidogrel in treatment of acute ST-segment elevation myocardial infarction

Objective To investigate and analyze the clinical efficacy of thrombolysis combined with clopidogrel in the treatment of acute ST-segment elevation myocardial infarction. Methods Eighty-four patients with acute ST-segment elevation myocardial infarction admitted to our hospital from January 2007 to January 2014 were included in the study. These patients were divided into control group （n=42） and observation group （n=42） using a random number table. The control group received conventional thrombolysis, while the observation group received thrombolysis combined with clopidogrel. The two groups were compared in terms of the number of anginal attacks and duration of each anginal attack, as well as the recurrence rate of myocardial infarction and mortality. Results Compared with the control group, the observation group had significantly reduced number of anginal attacks and duration of each anginal attack （P〈0.05）. In addition, the observation group had significantly lower recurrence rate of myocardial infarction and mortality than the control group （P〈0.05）. There was no significant difference in the incidence of adverse events between the two groups （P〉 0.05）. Conclusion Thrombolysis combined with clopidogrel has significant efficacy, reduces the number of anginal attacks and the recurrence rate of myocardial infarction, and significantly improves patients＇ prognosis in the treatment of acute ST-segment elevation myocardial infarction, and it has great clinical significance.